MMMiao Mingxing

Miao Mingxing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Miao Mingxing has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Guiqin Huang

    School of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China

    1 shared publication
  • Guo Yujuan

    Department of Physiology and Pharmacology, China Pharmaceutical University, Nanjing, China

    1 shared publication
  • Lingpeng Zhu

    The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu 214023, China

    1 shared publication
  • Liu Jingyan

    Department of Physiology and Pharmacology, China Pharmaceutical University, Nanjing, China

    1 shared publication
  • Menghui Ren

    Department of Physiology and Pharmacology, China Pharmaceutic University, Nanjing, Jiangsu, China

    1 shared publication
  • Run Cheng

    School of Basic Medical Science and Clinical Pharmacy, China Pharmaceutic University, Nanjing, Jiangsu 210009, China

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy

    by Guiqin Huang, Yawen Cai, Menghui Ren, Xiaoyu Zhang, Yu Fu, Run Cheng, Yingdi Wang, Mingxing Miao, Lingpeng Zhu, Tianhua Yan


  • Salidroside Attenuates LPS-Induced Acute Lung Injury in Rats

    by Liu Jingyan, Guo Yujuan, Yang Yiming, Zhu Lingpeng, Yan Tianhua, Miao Mingxing

    The purpose of the present study was to investigate the effects of salidroside (Sal) on lung injury in lipopolysaccharide (LPS)-induced endotoxemic in vitro and in vivo. SD rats were randomly divided into five groups: control group, LPS group (15 mg kg−1), LPS plus dexamethasone (2 mg kg−1), and LPS plus Sal groups with different Sal doses (20 mg kg−1, 40 mg kg−1). Wet-to-dry weight (W/D) ratio was performed. Hematoxylin–eosin (HE) staining of lung was performed. Lung level of myeloperoxidase (MPO) was measured. Serum levels of the activities of the anti-oxidant superoxide dismutase (SOD), glutathione peroxidase (GSH-px), glutathione (GSH), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were measured. Caveolin-1 and TLR/NF-κB pathway proteins were detected by Western blot. In vitro, we evaluated the protective effect of Sal on A549 cell line induced by LPS. The activities of the antioxidant SOD, CAT, GSH and GPX, TNF-α, IL-6, and IL-1β in cellular supernatant were measured. Caveolin-1 and TLR/NF-κB pathway was examined by Western blot. As a result, Sal significantly attenuated the above indices. In addition, Sal exerts pronounced protective effects in rats subjected to LPS possibly through inhibiting the caveolin-1 and TLR/NF-κB pathway in vivo. Our results indicated that Sal could be a potential therapeutic agent for the treatment of lung injury disease.